Trimetrexate
From Wikipedia, the free encyclopedia
 |
|
|
Trimetrexate
|
|
| Systematic (IUPAC) name | |
| 5-methyl-6-[(3,4,5-trimethoxyphenyl) aminomethyl] quinazoline-2,4-diamine | |
| Identifiers | |
| CAS number | 52128-35-5 |
| ATC code | P01AX07 |
| PubChem | 5583 |
| DrugBank | APRD00268 |
| Chemical data | |
| Formula | C19H23N5O3 |
| Mol. weight | 369.418 g/mol |
| Pharmacokinetic data | |
| Bioavailability | VD: 20-30 Liters |
| Metabolism | Oxidative O-demethylation, followed by conjugation with glucuronide or sulfate |
| Half life | 11 to 12 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Trimetrexate is a quinazoline derivative and dihydrofolate reductase inhibitor used with leucovorin in treating pneumocystis jiroveci pneumonia.
[edit] External links
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
